Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo
- Resource Type
- Article
- Source
- In
Kidney International April 2023 103(4):772-781 - Subject
- Language
- ISSN
- 0085-2538